175 related articles for article (PubMed ID: 24362902)
1. An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.
Shi J; Zuo H; Ni L; Xia L; Zhao L; Gong M; Nie D; Gong P; Cui D; Shi W; Chen J
Neurol Sci; 2014 Jun; 35(6):839-45. PubMed ID: 24362902
[TBL] [Abstract][Full Text] [Related]
2. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
4. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
5. Blockade of Glutathione Metabolism in
Tang X; Fu X; Liu Y; Yu D; Cai SJ; Yang C
Mol Cancer Ther; 2020 Jan; 19(1):221-230. PubMed ID: 31548295
[TBL] [Abstract][Full Text] [Related]
6. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
7. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
8. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
[TBL] [Abstract][Full Text] [Related]
9. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.
Baldewpersad Tewarie NM; Burgers IA; Dawood Y; den Boon HC; den Brok MG; Klunder JH; Koopmans KB; Rademaker E; van den Broek HB; van den Bersselaar SM; Witjes JJ; Van Noorden CJ; Atai NA
Med Hypotheses; 2013 Jun; 80(6):728-31. PubMed ID: 23541771
[TBL] [Abstract][Full Text] [Related]
10. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
Bleeker FE; Atai NA; Lamba S; Jonker A; Rijkeboer D; Bosch KS; Tigchelaar W; Troost D; Vandertop WP; Bardelli A; Van Noorden CJ
Acta Neuropathol; 2010 Apr; 119(4):487-94. PubMed ID: 20127344
[TBL] [Abstract][Full Text] [Related]
11. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
13. Role of isocitrate dehydrogenase in glioma.
Alexander BM; Mehta MP
Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
[TBL] [Abstract][Full Text] [Related]
14. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism.
Yu D; Liu Y; Zhou Y; Ruiz-Rodado V; Larion M; Xu G; Yang C
Proc Natl Acad Sci U S A; 2020 May; 117(18):9964-9972. PubMed ID: 32312817
[TBL] [Abstract][Full Text] [Related]
15. Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction.
Khan M; Yi F; Rasul A; Li T; Wang N; Gao H; Gao R; Ma T
IUBMB Life; 2012 Sep; 64(9):783-94. PubMed ID: 22837216
[TBL] [Abstract][Full Text] [Related]
16. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
[TBL] [Abstract][Full Text] [Related]
17. Cassane diterpenoid derivative induces apoptosis in IDH1 mutant glioma cells through the inhibition of glutaminase in vitro and in vivo.
Huang GD; Chen FF; Ma GX; Li WP; Zheng YY; Meng XB; Li ZY; Chen L
Phytomedicine; 2021 Feb; 82():153434. PubMed ID: 33529962
[TBL] [Abstract][Full Text] [Related]
18. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]